Novartis Aktie

102,26 EUR +2,74 EUR +2,75 %

16:23:24

L&S

96,86 CHF +3,06 CHF +3,26 %

16:10:39

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.193,25 Mrd. EUR

KGV13,21Div. Rendite3,89%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

12:26BenzingaNovartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries

07:00GlobeNewswireNovartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

06:59Dow JonesPress Release: Novartis continues strong momentum -5-

WerbungNovartis-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

06:59Dow JonesPress Release: Novartis continues strong momentum -3-

06:59Dow JonesPress Release: Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

30.01.25BenzingaAbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?

28.01.25ZacksNovartis to Report Q4 Earnings: What's in the Offing?

23.01.25ZacksDo Options Traders Know Something About Alcon (ALC) Stock We Don't?

22.01.25BenzingaGoogle Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

16.01.25BenzingaOutlook Therapeutics Vision Loss Drug At Par With Novartis Drug

13.01.25GlobeNewswireNovartis Entresto® US patent upheld by US Court of Appeals

13.01.25Dow JonesPress Release: Novartis Entresto(R) US patent upheld by US Court of Appeals

07.01.25ZacksWhy Novartis (NVS) is a Top Value Stock for the Long-Term

31.12.24ZacksHere's Why Novartis (NVS) is a Strong Growth Stock

30.12.24GlobeNewswireNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

23.12.24ZacksHere's Why Alcon (ALC) is a Strong Growth Stock

17.12.24ZacksAre Investors Undervaluing Novartis (NVS) Right Now?

13.12.24ZacksReasons to Retain Alcon Stock in Your Portfolio for Now

13.12.24ZacksThe Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI Technology

12.12.24ZacksTop Stock Reports for Mastercard, Procter & Gamble & Novartis

10.12.24GlobeNewswireLonger-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) -3-

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) -2-

10.12.24Dow JonesPress Release: Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast ca...

09.12.24ZacksNovartis Announces Positive Results From Late-Stage Study on Fabhalta

08.12.24GlobeNewswireLonger-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

06.12.24BenzingaNovartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

06.12.24ZacksWhy Alcon (ALC) is a Top Growth Stock for the Long-Term

06.12.24GlobeNewswireNew Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

06.12.24Dow JonesPress Release: New Phase IIIB data shows Novartis -2-

06.12.24Dow JonesPress Release: New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switc...

04.12.24ZacksWhy Novartis (NVS) is a Top Growth Stock for the Long-Term

03.12.24ZacksNovartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

02.12.24BenzingaPTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

02.12.24PR NewswirePTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

02.12.24ZacksThe Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

27.11.24GlobeNewswireNovartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

27.11.24Dow JonesPress Release: Novartis Kisqali(R) receives -3-

27.11.24Dow JonesPress Release: Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of...

25.11.24GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.